Pliant Historical Income Statement

PLRX Stock

USD 13.80 0.27 2.00%

Historical analysis of Pliant Therapeutics income statement accounts such as Selling General Administrative of 29.4 M, Total Revenue of 1.5 M, Other Operating Expenses of 95.9 M or Research Development of 80.7 M can show how well Pliant Therapeutics performed in making a profits. Evaluating Pliant Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Pliant Therapeutics's future profits or losses.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Pliant Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Pliant Therapeutics is a good buy for the upcoming year.

Net Income Gross Profit

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pliant Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Pliant Stock please use our How to Invest in Pliant Therapeutics guide.

About Pliant Income Statement Analysis

Pliant Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Pliant Therapeutics shareholders. The income statement also shows Pliant investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Pliant Therapeutics Income Statement Chart

At this time, Pliant Therapeutics' Interest Expense is fairly stable compared to the past year. Net Interest Income is likely to rise to about 20.2 M in 2024, despite the fact that EBIT is likely to grow to (152.1 M).

Selling General Administrative Other Operating Expenses Operating Income Research Development Total Operating Expenses

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Pliant Therapeutics. It is also known as Pliant Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Operating Income

Operating Income is the amount of profit realized from Pliant Therapeutics operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Pliant Therapeutics is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Most accounts from Pliant Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Pliant Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pliant Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Pliant Stock please use our How to Invest in Pliant Therapeutics guide.At this time, Pliant Therapeutics' Interest Expense is fairly stable compared to the past year. Net Interest Income is likely to rise to about 20.2 M in 2024, despite the fact that EBIT is likely to grow to (152.1 M).

	2021	2022	2023	2024 (projected)
Interest Income	272K	4.7M	20.5M	21.5M
Net Interest Income	272K	3.9M	19.2M	20.2M

Interest Income Net Interest Income

Pliant Therapeutics income statement Correlations

	Ebit	Net Interest Income	Interest Income	Depreciation And Amortization	Selling General Administrative	Other Operating Expenses	Operating Income	Net Income From Continuing Ops	Research Development	Ebitda	Total Operating Expenses	Reconciled Depreciation	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Gross Profit	Non Operating Income Net Other	Cost Of Revenue
Ebit		-0.91	-0.91	-0.74	-0.87	-0.89	0.99	0.93	-0.84	0.99	-0.89	-0.79	0.99	-0.9	0.99	-0.21	0.85	-0.98	0.66
Net Interest Income	-0.91		1.0	0.44	0.75	0.75	-0.93	-0.83	0.72	-0.91	0.75	0.63	-0.91	1.0	-0.91	0.48	-0.73	0.9	-0.89
Interest Income	-0.91	1.0		0.46	0.76	0.76	-0.94	-0.84	0.73	-0.92	0.76	0.64	-0.92	1.0	-0.92	0.47	-0.74	0.91	-0.88
Depreciation And Amortization	-0.74	0.44	0.46		0.79	0.76	-0.67	-0.76	0.81	-0.69	0.76	0.87	-0.7	0.45	-0.69	-0.43	-0.82	0.77	-0.07
Selling General Administrative	-0.87	0.75	0.76	0.79		0.92	-0.84	-0.92	0.98	-0.84	0.92	0.93	-0.85	0.76	-0.84	-0.09	-0.92	0.86	-0.6
Other Operating Expenses	-0.89	0.75	0.76	0.76	0.92		-0.87	-0.79	0.91	-0.87	1.0	0.84	-0.87	0.76	-0.87	-0.01	-0.76	0.87	-0.58
Operating Income	0.99	-0.93	-0.94	-0.67	-0.84	-0.87		0.92	-0.8	1.0	-0.87	-0.73	1.0	-0.93	1.0	-0.3	0.81	-0.98	0.71
Net Income From Continuing Ops	0.93	-0.83	-0.84	-0.76	-0.92	-0.79	0.92		-0.89	0.91	-0.79	-0.86	0.92	-0.84	0.91	-0.07	0.97	-0.92	0.62
Research Development	-0.84	0.72	0.73	0.81	0.98	0.91	-0.8	-0.89		-0.79	0.91	0.98	-0.8	0.73	-0.79	-0.21	-0.93	0.83	-0.56
Ebitda	0.99	-0.91	-0.92	-0.69	-0.84	-0.87	1.0	0.91	-0.79		-0.87	-0.73	1.0	-0.91	1.0	-0.29	0.81	-0.98	0.68
Total Operating Expenses	-0.89	0.75	0.76	0.76	0.92	1.0	-0.87	-0.79	0.91	-0.87		0.84	-0.87	0.76	-0.87	-0.01	-0.76	0.87	-0.58
Reconciled Depreciation	-0.79	0.63	0.64	0.87	0.93	0.84	-0.73	-0.86	0.98	-0.73	0.84		-0.74	0.65	-0.73	-0.36	-0.94	0.79	-0.42
Income Before Tax	0.99	-0.91	-0.92	-0.7	-0.85	-0.87	1.0	0.92	-0.8	1.0	-0.87	-0.74		-0.9	1.0	-0.27	0.81	-0.98	0.67
Total Other Income Expense Net	-0.9	1.0	1.0	0.45	0.76	0.76	-0.93	-0.84	0.73	-0.91	0.76	0.65	-0.9		-0.91	0.46	-0.74	0.9	-0.89
Net Income	0.99	-0.91	-0.92	-0.69	-0.84	-0.87	1.0	0.91	-0.79	1.0	-0.87	-0.73	1.0	-0.91		-0.29	0.81	-0.98	0.67
Income Tax Expense	-0.21	0.48	0.47	-0.43	-0.09	-0.01	-0.3	-0.07	-0.21	-0.29	-0.01	-0.36	-0.27	0.46	-0.29		0.16	0.19	-0.61
Gross Profit	0.85	-0.73	-0.74	-0.82	-0.92	-0.76	0.81	0.97	-0.93	0.81	-0.76	-0.94	0.81	-0.74	0.81	0.16		-0.85	0.5
Non Operating Income Net Other	-0.98	0.9	0.91	0.77	0.86	0.87	-0.98	-0.92	0.83	-0.98	0.87	0.79	-0.98	0.9	-0.98	0.19	-0.85		-0.62
Cost Of Revenue	0.66	-0.89	-0.88	-0.07	-0.6	-0.58	0.71	0.62	-0.56	0.68	-0.58	-0.42	0.67	-0.89	0.67	-0.61	0.5	-0.62

Click cells to compare fundamentals

Pliant Therapeutics Account Relationship Matchups

Pliant Therapeutics income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Ebit	(1.2M)	(41.6M)	(20.0M)	(122.5M)	(160.1M)	(152.1M)
Net Income Applicable To Common Shares	(6.9M)	(41.5M)	(19.7M)	(123.3M)	(111.0M)	(105.4M)
Net Interest Income	816K	478K	272K	3.9M	19.2M	20.2M
Interest Income	816K	478K	272K	4.7M	20.5M	21.5M
Depreciation And Amortization	1.1M	1.3M	1.5M	3.7M	1.8M	1.9M
Selling General Administrative	10.9M	17.3M	27.6M	39.9M	57.9M	29.4M
Total Revenue	57.1M	41.8M	7.6M	9.7M	1.6M	1.5M
Other Operating Expenses	58.3M	83.5M	27.6M	136.9M	185.7M	95.9M
Operating Income	(1.2M)	(41.6M)	(20.0M)	(127.2M)	(184.1M)	(174.9M)
Net Income From Continuing Ops	(631K)	(41.5M)	(97.3M)	(123.3M)	(155.3M)	(147.5M)
Research Development	47.4M	66.2M	77.5M	96.9M	127.8M	80.7M
Ebitda	(118K)	(40.3M)	(18.5M)	(118.8M)	(158.2M)	(150.3M)
Total Operating Expenses	58.3M	83.5M	27.6M	136.9M	185.7M	95.9M
Reconciled Depreciation	1.1M	1.3M	1.5M	1.8M	1.8M	1.5M
Income Before Tax	(631K)	(41.5M)	(19.7M)	(123.3M)	(161.3M)	(153.3M)
Total Other Income Expense Net	600K	112K	272K	3.9M	22.8M	23.9M
Net Income	185K	(39.7M)	(17.9M)	(121.5M)	(161.3M)	(153.3M)
Income Tax Expense	(816K)	(1.8M)	(1.8M)	(1.8M)	1.7M	1.8M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Additional Tools for Pliant Stock Analysis

When running Pliant Therapeutics' price analysis, check to measure Pliant Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pliant Therapeutics is operating at the current time. Most of Pliant Therapeutics' value examination focuses on studying past and present price action to predict the probability of Pliant Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pliant Therapeutics' price. Additionally, you may evaluate how the addition of Pliant Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Pliant Historical Income Statement

About Pliant Income Statement Analysis

Pliant Therapeutics Income Statement Chart

Other Operating Expenses

Operating Income

Total Operating Expenses

Pliant Therapeutics income statement Correlations

Pliant Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Pliant Therapeutics income statement Accounts

Also Currently Popular

Additional Tools for Pliant Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Interest Expense	Ebit
Net Income Applicable To Common Shares	Net Interest Income
Interest Income	Depreciation And Amortization
Selling General Administrative	Total Revenue
Other Operating Expenses	Operating Income
Net Income From Continuing Ops	Research Development
Ebitda	Total Operating Expenses
Reconciled Depreciation	Income Before Tax
Total Other Income Expense Net	Net Income
Income Tax Expense	Gross Profit
Non Operating Income Net Other	Cost Of Revenue

Interest Income	+ 1.0	Net Interest Income
Total Other Income Expense Net	+ 1.0	Net Interest Income
Total Other Income Expense Net	+ 1.0	Interest Income
Total Operating Expenses	+ 1.0	Other Operating Expenses
Ebitda	+ 1.0	Operating Income
Income Before Tax	+ 1.0	Operating Income

Non Operating Income Net Other	- 0.98	Net Income
Non Operating Income Net Other	- 0.98	Income Before Tax
Non Operating Income Net Other	- 0.98	Ebitda
Non Operating Income Net Other	- 0.98	Operating Income
Non Operating Income Net Other	- 0.98	Ebit
Gross Profit	- 0.94	Reconciled Depreciation